Outlook Therapeutics, Inc.
$0.37
▲
4.29%
2026-04-21 08:42:01
outlooktherapeutics.com
NCM: OTLK
Explore Outlook Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$38.71 M
Current Price
$0.37
52W High / Low
$3.39 / $0.16
Stock P/E
—
Book Value
$-0.6
Dividend Yield
—
ROCE
246.27%
ROE
118.61%
Face Value
—
EPS
$-2.89
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
17
Beta
0.19
Debt / Equity
-0.94
Current Ratio
0.35
Quick Ratio
0.31
Forward P/E
-0.91
Price / Sales
126.63
Enterprise Value
$48.9 M
EV / EBITDA
-0.83
EV / Revenue
237.72
Rating
Buy
Target Price
$4.17
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Strong operating margin profile.
- Valuation is not stretched on P/E basis.
Cons
- Current ratio suggests tighter short-term liquidity.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Imunon, Inc. | $3.1 | — | $12.36 M | — | -191.16% | -2.56% | $41.22 / $2.52 | $2.42 |
| 2. | Kiora Pharmaceuticals, Inc. | $2.52 | — | $9.96 M | — | -45.87% | -51.74% | $4.18 / $1.76 | $4.29 |
| 3. | Cue Biopharma, Inc. | $0.85 | — | $82.97 M | — | -92.35% | -121.11% | $1.03 / $0.17 | $0.27 |
| 4. | Vyome Holdings, Inc. | $2.35 | — | $16.49 M | — | -73.02% | 1053.07% | $56.36 / $1.75 | $0.41 |
| 5. | MediciNova, Inc. | $1.47 | — | $71.37 M | — | -31.77% | -25.5% | $1.96 / $1.17 | $0.84 |
| 6. | IO Biotech, Inc. | $0.01 | — | $0.55 M | — | -197.41% | -2.4% | $2.79 / $0.01 | $0.01 |
| 7. | Pharvaris N.V. | $28.97 | — | $1.86 B | — | -54.28% | -65.19% | $29.89 / $13.6 | $5.56 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | -1.21 M | -0.09 M | 1.51 M | 0 M | 0 M | — |
| Operating Profit | -13.48 M | -17.31 M | -15.75 M | -12.39 M | -21.61 M | — |
| Net Profit | -23.06 M | -13.29 M | -20.15 M | -46.36 M | 17.38 M | — |
| EPS in Rs | -0.22 | -0.13 | -0.19 | -0.44 | 0.17 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.41 M | 0 M | 0 M | 0 M |
| Operating Profit | -67.06 M | -71.7 M | -53.13 M | -63.07 M |
| Net Profit | -62.42 M | -75.37 M | -58.98 M | -66.05 M |
| EPS in Rs | -0.6 | -0.72 | -0.56 | -0.63 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 18.58 M | 28.82 M | 32.3 M | 28.53 M |
| Total Liabilities | 50.77 M | 101.9 M | 46.74 M | 19.79 M |
| Equity | -32.19 M | -73.08 M | -14.44 M | 8.74 M |
| Current Assets | 17.39 M | 27.42 M | 30.98 M | 27.52 M |
| Current Liabilities | 45.81 M | 42.55 M | 46.73 M | 19.73 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -51.83 M | -68.79 M | -42.97 M | -56.67 M |
| Investing CF | — | — | — | — |
| Financing CF | 44.98 M | 60.33 M | 48.97 M | 59.59 M |
| Free CF | -51.83 M | -68.79 M | -42.97 M | -56.67 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -27.78% | 10.7% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-03-14 | 1:0.05 |